Wolfgang Miesbach on FRONTIER2 Data: Mim8 Prophylaxis Achieves a Median ABR of Zero in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“FRONTIER2 delivers impressive ASH 52-week data presented by Lentz Steven: Adults and adolescents with haemophilia A maintained robust bleed protection with Mim8 prophylaxis, regardless of inhibitor status or prior treatment regimen:
- Median ABR of zero across extension period (weeks 26-52)
QW dosing: estimated mean ABR 1.28 [95% CI: 0.78–2.08]
QM dosing: estimated mean ABR 1.54 [95% CI: 0.92–2.59] - Prior on-demand patients saw dramatic 97–99% ABR reduction
- CFC prophylaxis patients achieved 42–48% further ABR reduction compared to prior treatment
Safety profile and over 270+ patient-years of exposure:
- No thromboembolic events
- No hypersensitivity reactions
- No coagulation abnormalities
- Injection-site reactions in <1% of administrations (all mild, transient)
- 82–84% of AEs mild; 66–88% unrelated to Mim8sciencehub.novonordisk
Anti-Mim8 antibodies in 7% of patients—all low/medium titer, zero clinical impact
What is Mim8?
MFactor VIIIa mimetic bispecific antibody bridges activated FIX/FX on platelet surfaces
Half-life: ~1 month (enables QW or QM dosing flexibility)
Potency: 13–18× more effective than emicizumab preclinically
Take away
96% completion rate through 52 weeks reflects both tolerability and patient satisfaction. The consistency of efficacy with sustained zero median bleeds across 6+ months—combined with minimal safety signals—establishes Mim8 as a durable, flexible prophylactic option for haemophilia A. FRONTIER4 extension study now enrolling.”
Read more posts from Wolfgang Miesbach on Hemostasis Today.
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit
-
Oct 9, 2026, 00:46Paris Margaritis: Assays vs Outcomes – Connecting FVIII Expression to Bleeding Phenotype in Hemophilia A
-
Oct 9, 2026, 00:39Rodrigo Arreola Diaz: The Rise of Concizumab for Hemophilia A and B
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours